Original Article

Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease

Yong-Ming Zhou1, Ming-Jiang Li2,3, Yan-Li Zhou2,3, Le-Le Ma2,3, Xin Yi2,3

1Department of Geriatrics, Renmin Hospital of Wuhan University, Wuhan 430060, China; 2Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; 3Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China

Received August 14, 2015; Accepted October 6, 2015; Epub November 15, 2015; Published November 30, 2015

Abstract: Objective: Growth differentiation factor-15 (GDF-15) has been identified as a strong biomarker of cardiovascular diseases; however, no evidence are available concerning the relationship of GDF-15 and atrial fibrosis in patients with atrial fibrillation (AF) and rheumatic heart disease (RHD). Methods: Twenty patients with rheumatic heart disease were divided into two groups, 10 cases with AF and 10 cases with sinus rhythm (SR). Clinical data and blood samples were collected; left atrial appendage was taken by the surgeon in the process of valve replacement. Masson stained sections and mRNA levels of cardiac fibrosis biomarkers were used to determine the level of cardiac fibrosis, the expression level of GDF-15 was evaluated via immunohistochemistry, enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (PCR). Results: Compared with SR group, more collagen deposited in the atrial tissue of AF group. The distribution of GDF-15 in the AF group was significantly higher than SR group (P<0.05). In addition, plasma GDF-15 level and mRNA level of GDF-15 in atrial tissue of AF showed the same trend as the result of immunohistochemistry. After linear correlation analysis, the expression level of GDF-15 was found to be positively related to the degree of cardiac fibrosis. Conclusion: GDF-15 might involve in the development and maintenance of atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease, and GDF-15 could be used as a novel biomarker to evaluate myocardial fibrosis in the future.

Keywords: Growth differentiation factor-15, atrial fibrosis, atrial fibrillation, rheumatic heart disease

Introduction

Atrial fibrillation (AF) is the common clinical manifestation of many cardiovascular diseases, such as rheumatic heart disease, coronary heart disease, hypertension, cardiomyopathy, congenital heart disease, pericardial diseases and other cardiovascular disease [1-3]. AF can seriously affect human health, in addition, which could cause serious cardiovascular and cerebrovascular events, has a high morbidity and mortality. Both clinical and basic researches have shown that atrial fibrosis is the most prominent manifestation of atrial structural remodeling in patients with atrial fibrillation, which is due to the heterogeneity of electrical conduction in atrial myocardium, which makes AF easy to occur and maintain [4-6]. Therefore, to block the remodeling of atrial structure maybe a better way to prevent the development and deterioration of atrial fibrillation. Growth differentiation factor-15 (GDF-15) is a member of transforming growth factor (TGF) of beta super family. Recent studies have confirmed that GDF-15 participates in a variety of cardiovascular diseases including acute myocardial ischemia, ischemia reperfusion injury and so on, which can provide prognostic evaluation of ST segment elevation in myocardial infarction patients [7, 8]. It is reported that the expression level of GDF-15 is significantly increased in myocardial tissue and peripheral blood [9-11]. The level of peripheral blood GDF-15 was also elevated in patients with chronic heart failure, and was associated with the prognosis of heart failure [12-14]. However, whether GDF-15 could reflect the degree of myocardial fibrosis after AF, whether associated with cardiac fibrosis as...
GDF-15 positively related to atrial fibrosis in atrial fibrillation patients

a biological indicator is still unclear. Therefore, this study aimed to investigate the relationship of GDF-15 and atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease.

Materials and methods

**Human myocardium samples collection and processing**

This study was approved by the Ethics Committee of Renmin Hospital of Wuhan University (Wuhan, China) and the samples were obtained according to the regulations of Renmin Hospital of Wuhan University. Twenty patients aged from 30 to 70 with rheumatic heart disease (RHD) who underwent valve replacement served as subjects in the present study. They were divided into two groups: 10 in the sinus rhythm (SR) group and 10 in the atrial fibrillation (AF) group. Exclusion criteria in the study as follows: infective endocarditis, hyperthyroidism, serious liver, kidney, lung dysfunction, malignant tumor, coronary atherosclerotic heart disease and chronic pulmonary heart disease. About 200 mg myocardium samples were collected before extracorporeal circulation established by the surgeon from the right atrium of patients. Each sample was divided into two parts after removed connective tissue and residual blood, one part was quickly put into liquid nitrogen jar and immediately transferred to -80°C refrigerator, another part was immediately washed with saline solution and fixed with 10% neutral buffered formalin for paraffin section.

**Materials**

GDF-15 Human ELISA Kit (ab155432) was obtained from Abcam. Primary antibody against GDF-15 (ab39999) was purchased from Abcam. TRIzol was purchased from Invitrogen Life Technologies (#15596018). Transcriptor First Strand cDNA Synthesis Kit (#0489686001) was purchased from Roche. Power SYBR® Green PCR Master Mix (#4367659) was purchased from Life Technologies.

**Masson staining**

Evidence of interstitial collagen deposition was visualized using Masson staining, and collagen volume (%) was measured using an image quantitative digital analysis system (Image-Pro plus 6.0). Briefly, myocardium tissues were fixed in 10% neutral buffered formalin for at least 24 hours, and embed in paraffin wax according to embedding machine manufactures instructions. Prepare 8 µm sections on the microtome and place on clean, positively-charged microscope slides. Heat in tissue-drying oven for 1 hour at 60°C. After deparaffinization and rehydration through 100% alcohol, 95% alcohol and 70% alcohol, the slides were washed in distilled water, and then re-fixed in Bouin’s solution for 1 hour at 56°C to improve staining quality although this step is not absolutely necessary. Rinse the slides in running tap water for 10 minutes to remove the yellow colour. Firstly, stain in Weigert’s iron hematoxylin working solution for 10 minutes; rinse them in running warm tap water for 10 minutes and wash in distilled water. And then stain in Biebrich scarlet-acid fuchsin solution for 10 minutes and wash in distilled water. Differenciate in phosphomolybdic-phosphotungstic acid solution for 10 minutes until collagen is not red. Transfer sections directly to aniline blue solution and stain for 5 minutes; rinse them in distilled water and differentiate in 1% acetic acid solution for 2 minutes, wash in distilled water. Dehydrate very quickly through 95% ethyl alcohol, absolute ethyl alcohol and clear in xylene, lastly mount with resinous mounting medium. Collagen was stained for blue, but muscle and cytoplasm were stained for red.

**Immunohistochemistry**

Deposition of GDF-15 in myocardium tissues was measured by the method of immunohistochemistry. As mentioned above, after fixed, embed, sectioned, deparaffinization and rehydration, we chose the most common method of antigen retrieval just as heat-mediated retrieval in citrate buffer. And add 100 µl blocking solution for per slide; incubate 30 minutes at room temperature. Drain the blocking solution from slides; apply 100 µl per slide of diluted primary antibody against GDF-15 at recommended concentration of 1:100; incubate overnight at 4°C. After washed with TBST, apply 100 µl per slide of diluted conjugated secondary antibody and incubate for 30 minutes at room temperature. Apply color development by the method of enzyme substrate for 30 minutes, wash slides in TBST and distilled water, and then dehydrate and mount slides. Brown-yellow granules in myocardium tissues meant a positive result.
GDF-15 positively related to atrial fibrosis in atrial fibrillation patients

**Table 1. Expansive left atrial diameter showed in AF patients with RHD**

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>SR (n = 10)</th>
<th>AF (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (m/w)</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>Age (y)</td>
<td>49.60±7.69</td>
<td>48.80±7.38</td>
</tr>
<tr>
<td>AF time (m)</td>
<td>-</td>
<td>15.70±4.50</td>
</tr>
<tr>
<td>NYHA (II/III)</td>
<td>7/3</td>
<td>6/4</td>
</tr>
<tr>
<td>LAD (mm)</td>
<td>34.30±3.95</td>
<td>51.60±5.36*</td>
</tr>
<tr>
<td>RAD (mm)</td>
<td>37.20±2.74</td>
<td>37.60±2.99</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>57.70±3.68</td>
<td>55.20±3.61</td>
</tr>
</tbody>
</table>

Note: Gender and grade of heart function were compared by using Fisher exact probability method; m/w = male/female; y = year; m = month; NYHA = New York heart function classification; LAD = left atrial diameter; RAD = right atrial diameter; LVEF = left ventricular ejection fraction; *P<0.05.

Computer image analysis was used to determine density of the positively stained area and relative quantitative analysis.

**Enzyme-linked immunosorbent assay (ELISA)**

Plasma GDF-15 in this study was detected by the method of enzyme-linked immunosorbent assay (ELISA). Briefly, add 100 μL of each standard and sample into appropriate wells. Cover well and incubate for 2.5 hours at room temperature with gentle shaking. Discard the solution and wash with Wash Solution by using a multi-channel Pipette. After the last wash, remove any remaining Wash Buffer by aspirating. Invert the plate and blot it against clean paper towels. Add 100 μL prepared biotinylated antibody to each well; incubate for 1 hour at room temperature with gentle shaking. Discard the solution and repeat the wash as before. Add 100 μL of prepared Streptavidin solution to each well and incubate for 45 minutes at room temperature with gentle shaking. Discard the solution and repeat the wash as before. Add 100 μL of TMB One-Step Substrate Reagent to each well; incubate for 30 minutes at room temperature in the dark with gentle shaking. Lastly, Add 50 μL of Stop Solution to each well and read at 450 nm immediately. For data calculation, calculate the mean absorbance for each set of duplicate standards, controls and samples, and subtract the average zero standard optical density. Plot the standard curve on log-log graph paper, with standard concentration on the x-axis and absorbance on the y-axis. Draw the best-fit straight line through standard points.

**Real-time polymerase chain reaction (PCR) analysis**

Expression levels of fibrosis biomarkers including CTGF, Collagen I and III were measured by real-time polymerase chain reaction (PCR) analysis. Total RNA was extracted from the myocardium tissues using TRIzol reagent according to the manufacturer’s instructions and the cDNA was synthesized using oligo (dT) primers with the transcriptor first-strand cDNA synthesis kit. Selected gene differences were confirmed by real-time PCR using SYBR-Green and the results were normalized against GAPDH gene expression. The sequences of all primers used in this study are presented as follows: GAPDH: 5'-GAGTCAACGGATTTGGTGTG-3' and 5'-TGATTTGAGGAGTCGC-3'; CTGF: 5'-TACCAGACAGGGCTCCTC-3' and 5'-CCGTCGTGACGACTCTACAG-3'; Collagen I: 5'-CCCAGCTACGCAGCCAAT-3' and 5'-CCGTCGTGACGACTCTACAG-3'; Collagen III: 5'-GAAGGGAAGGAGGACAACTTG-3' and 5'-TTTGCTTTGGTGCTTCTGCT-3'.

**Statistical analysis**

The data are expressed as the means ± standard deviation (SD). Differences between two groups were performed by an unpaired Student’s t-test using SPSS 19.0 statistical software. A value of P<0.05 was considered to indicate statistically significant difference.

**Results**

**Expansive left atrial diameter showed in AF patients with RHD**

All subjects were received preoperative routine testing of urine, stool, blood coagulation, blood biochemistry, X-ray, electrocardiograph, ultrasonic cardiogram and so on. General clinical characteristics included age, gender, past history, AF duration etc. There was no statistically difference in terms of gender, age, classification of cardiac function and LVEF between SR and AF groups (P>0.05). However, when compared with the SR group, it was shown that left atrial diameter (LAD) was remarkably expansive in AF patients (P<0.05) (Table 1).

**Accumulated collagen deposited in the myocardial interstitial of AF patients with RHD**

To investigate the role of atrial fibrillation in morphology of patients with rheumatic heart
GDF-15 positively related to atrial fibrosis in atrial fibrillation patients

GDF-15 levels positively related to atrial fibrosis in AF patients with RHD

To explore the relationship of GDF-15 and atrial fibrosis in AF group, we investigated the linear correlation analysis between them. We found that the plasma and mRNA level of GDF-15 in atrial tissues were all positively related to the degree of atrial fibrosis in the AF group (Table 2). Therefore, these results indicated that GDF-15 could be used as a novel biomarker to evaluate myocardial fibrosis in AF patients with rheumatic heart disease in the future.

Discussion

Atrial fibrillation is the most common persistent arrhythmia in clinic, which increases the risk of stroke and death [15, 16]. Epidemiological data...
GDF-15 positively related to atrial fibrosis in atrial fibrillation patients

show that there are about 800-1000 million of atrial fibrillation patients per year in China, which has become serious public health problem that seriously endanger the people’s health. The current view is that occurrence and maintenance of atrial fibrillation are closely related to atrial remodeling which includes electrical remodeling and structural remodeling, and atrial fibrosis is the most important part of the structural remodeling, collagen accumulation in interstitial cells would not only affect the entire mechanics of atrial function, but would also cause local electrical heterogeneity in conduction resulting in arrhythmias especially atrial fibrillation [17, 18]. In the present study, we observed that level of atrial fibrosis markedly increased via Masson staining and biomarkers respectively in atrial fibrillation patients with rheumatic heart disease; however, there were only fewer collagen fibers in the sinus rhythm group of patients, which consistent with previous views that atrial structural remodeling were closely related to the generation and maintenance of atrial fibrillation.

GDF-15 is a member of the transforming growth factor of beta super family, in order to reduce the inflammatory response which can inhibit cardiac hypertrophy, cardiac remodeling, cell apoptosis and activation of macrophages [19-21]. Under physiological conditions, GDF-15 is weakly expressed in cardiac tissues, but in the condition of inflammation or pressure overload, ischemia/reperfusion injury, heart failure, atherosclerosis and other stress conditions, the expression of GDF-15 can be activated in cardiomyocytes [22-24]. Recent studies indicate

Table 2. GDF-15 levels positively related to atrial fibrosis in AF patients with RHD (r, correlation coefficient)

<table>
<thead>
<tr>
<th></th>
<th>Plasma GDF-15</th>
<th>mRNA of GDF-15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen Volume</td>
<td>0.622</td>
<td>0.752</td>
</tr>
<tr>
<td>CTGF</td>
<td>0.822</td>
<td>0.783</td>
</tr>
<tr>
<td>Collagen I</td>
<td>0.837</td>
<td>0.678</td>
</tr>
<tr>
<td>Collagen III</td>
<td>0.862</td>
<td>0.817</td>
</tr>
</tbody>
</table>

Figure 2. Elevated GDF-15 levels in plasma and myocardial tissues of AF patients with RHD. A. Level of GDF-15 in plasma was significantly increased in AF patients with rheumatic heart disease. B. Representative immunohistochemistry staining images of GDF-15 in SR and AF patients with rheumatic heart disease. C. The mRNA levels of GDF-15 in the atrial tissues of SR and AF patients with rheumatic heart disease. *P<0.05 vs. SR group.
GDF-15 positively related to atrial fibrosis in atrial fibrillation patients

that GDF-15 is an independent predictor of adverse outcomes in patients with heart failure, acute coronary syndrome and acute pulmonary embolism [25, 26]. In addition, recent studies have found that inflammation may play an important role in the occurrence and maintenance of atrial fibrillation [27, 28]. Therefore, GDF-15 as an inflammatory marker, it is speculated that it may be involved in the occurrence and development of atrial fibrillation. In this study, our result firstly proved that compared with SR group, more GDF-15 diffusely distributed in the myocardium of atrial fibrillation patients, and the plasma level of GDF-15 was also significantly elevated in atrial fibrillation group. Most importantly, we found that the plasma and mRNA level of GDF-15 in atrial tissues were all positively related to the degree of atrial fibrosis in the atrial fibrillation, which would be expected to become one of the important biomarkers for predicting atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease.

In conclusion, we show that GDF-15 might involve in the development and maintenance of atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease, and GDF-15 could be used as a novel biomarker to evaluate myocardial fibrosis in patients with atrial fibrillation and rheumatic heart disease in the future. However, there were still some limits in the present study as follows: 1) further expand the sample size to increase the intensity of the results; 2) explore the mechanism of elevated GDF-15, and to find a new target for the intervention of myocardial fibrosis in patients with atrial fibrillation and rheumatic heart disease.

Acknowledgements

We thank Prof. Jun Xia who helped us collect the samples and thank all of the members of Cardiovascular Research Institute of Wuhan University for their expert technical assistance and highly supportive advice. The present study was supported by grants from the Natural Science Foundation of Hubei Province (No. 2013CKB0004).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xin Yi, Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Jiefang Road 238, Wuhan 430060, China. Tel: 86-27-88041911-82150; Fax: 86-27-88041237; E-mail: yixin321624@126.com

References

GDF-15 positively related to atrial fibrosis in atrial fibrillation patients


